25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Adaptive Biotechnologies Corp
Buy, Hold or Sell?

Let's analyze Adaptive Biotechnologies Corp together

I guess you are interested in Adaptive Biotechnologies Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Adaptive Biotechnologies Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adaptive Biotechnologies Corp

I send you an email if I find something interesting about Adaptive Biotechnologies Corp.

1. Quick Overview

1.1. Quick analysis of Adaptive Biotechnologies Corp (30 sec.)










1.2. What can you expect buying and holding a share of Adaptive Biotechnologies Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.51
Expected worth in 1 year
$0.58
How sure are you?
11.1%

+ What do you gain per year?

Total Gains per Share
$-0.94
Return On Investment
-13.5%

For what price can you sell your share?

Current Price per Share
$6.92
Expected price per share
$3.981 - $8.95
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adaptive Biotechnologies Corp (5 min.)




Live pricePrice per Share (EOD)
$6.92
Intrinsic Value Per Share
$0.89 - $1.59
Total Value Per Share
$2.41 - $3.10

2.2. Growth of Adaptive Biotechnologies Corp (5 min.)




Is Adaptive Biotechnologies Corp growing?

Current yearPrevious yearGrowGrow %
How rich?$223.5m$411.4m-$149.4m-57.0%

How much money is Adaptive Biotechnologies Corp making?

Current yearPrevious yearGrowGrow %
Making money-$48.8m-$46m-$2.7m-5.6%
Net Profit Margin-110.3%-109.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Adaptive Biotechnologies Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#235 / 933

Most Revenue
#168 / 933

Most Profit
#807 / 933

Most Efficient
#450 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adaptive Biotechnologies Corp?

Welcome investor! Adaptive Biotechnologies Corp's management wants to use your money to grow the business. In return you get a share of Adaptive Biotechnologies Corp.

First you should know what it really means to hold a share of Adaptive Biotechnologies Corp. And how you can make/lose money.

Speculation

The Price per Share of Adaptive Biotechnologies Corp is $6.92. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adaptive Biotechnologies Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adaptive Biotechnologies Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.51. Based on the TTM, the Book Value Change Per Share is $-0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adaptive Biotechnologies Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.22-3.1%-0.33-4.8%-0.33-4.8%-0.31-4.5%-0.26-3.8%
Usd Book Value Change Per Share-0.12-1.7%-0.23-3.4%-0.21-3.1%-0.12-1.8%0.060.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.12-1.7%-0.23-3.4%-0.21-3.1%-0.12-1.8%0.060.8%
Usd Price Per Share5.12-4.21-7.16-21.58-18.92-
Price to Earnings Ratio-5.89--3.47--5.46--19.95--21.84-
Price-to-Total Gains Ratio-42.32--21.51--34.70--107.42--97.98-
Price to Book Ratio3.38-2.42-2.56-5.46-3.40-
Price-to-Total Gains Ratio-42.32--21.51--34.70--107.42--97.98-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.92
Number of shares144
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.23-0.12
Usd Total Gains Per Share-0.23-0.12
Gains per Quarter (144 shares)-33.68-17.68
Gains per Year (144 shares)-134.71-70.71
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-135-1450-71-81
20-269-2800-141-152
30-404-4150-212-223
40-539-5500-283-294
50-674-6850-354-365
60-808-8200-424-436
70-943-9550-495-507
80-1078-10900-566-578
90-1212-12250-636-649
100-1347-13600-707-720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.027.00.00.0%0.027.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.021.03.011.1%3.021.03.011.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.027.00.0%0.00.027.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.021.03.011.1%3.021.03.011.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adaptive Biotechnologies Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.121-0.234+93%-0.214+77%-0.123+1%0.056-316%
Book Value Per Share--1.5151.775-15%2.788-46%3.421-56%2.618-42%
Current Ratio--3.5194.169-16%5.088-31%5.371-34%5.063-31%
Debt To Asset Ratio--0.6000.569+5%0.475+26%0.422+42%0.466+29%
Debt To Equity Ratio--1.4971.330+13%0.907+65%0.780+92%0.641+134%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--664001520.960575100321.200+15%1116947999.760-41%3314546763.632-80%3534472077.556-81%
Eps---0.217-0.331+52%-0.332+53%-0.314+44%-0.264+22%
Ev To Ebitda Ratio---6.757-3.900-42%-6.586-3%-21.124+213%-27.938+313%
Ev To Sales Ratio--3.5753.223+11%6.359-44%27.142-87%30.190-88%
Free Cash Flow Per Share---0.186-0.194+4%-0.290+56%-0.307+65%-0.181-3%
Free Cash Flow To Equity Per Share---0.185-0.194+4%-0.287+55%-0.152-18%0.014-1430%
Gross Profit Margin--1.6411.466+12%1.559+5%1.481+11%1.498+10%
Intrinsic Value_10Y_max--1.589--------
Intrinsic Value_10Y_min--0.893--------
Intrinsic Value_1Y_max---0.976--------
Intrinsic Value_1Y_min---0.960--------
Intrinsic Value_3Y_max---2.068--------
Intrinsic Value_3Y_min---1.992--------
Intrinsic Value_5Y_max---2.117--------
Intrinsic Value_5Y_min---2.039--------
Market Cap1021246735.360+26%755604520.960621676571.200+22%1056296749.760-28%3184607413.632-76%2791866878.009-73%
Net Profit Margin---0.691-1.103+60%-1.097+59%-1.237+79%-1.150+67%
Operating Margin---0.628-1.038+65%-1.072+71%-1.201+91%-1.133+80%
Operating Ratio--1.7031.944-12%2.138-20%2.241-24%2.173-22%
Pb Ratio4.568+26%3.3802.416+40%2.557+32%5.456-38%3.402-1%
Pe Ratio-7.961-35%-5.890-3.469-41%-5.462-7%-19.953+239%-21.839+271%
Price Per Share6.920+26%5.1204.213+22%7.158-28%21.579-76%18.918-73%
Price To Free Cash Flow Ratio-9.315-35%-6.892-5.821-16%-6.764-2%-17.643+156%-18.100+163%
Price To Total Gains Ratio-57.193-35%-42.317-21.508-49%-34.704-18%-107.419+154%-97.982+132%
Quick Ratio--5.5856.648-16%8.243-32%8.433-34%8.098-31%
Return On Assets---0.057-0.080+38%-0.060+4%-0.056-2%-0.046-20%
Return On Equity---0.143-0.183+28%-0.115-20%-0.104-28%-0.080-44%
Total Gains Per Share---0.121-0.234+93%-0.214+77%-0.123+1%0.056-316%
Usd Book Value--223574000.000262012000.000-15%411413500.000-46%504930650.000-56%386301851.852-42%
Usd Book Value Change Per Share---0.121-0.234+93%-0.214+77%-0.123+1%0.056-316%
Usd Book Value Per Share--1.5151.775-15%2.788-46%3.421-56%2.618-42%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--664001520.960575100321.200+15%1116947999.760-41%3314546763.632-80%3534472077.556-81%
Usd Eps---0.217-0.331+52%-0.332+53%-0.314+44%-0.264+22%
Usd Free Cash Flow---27409000.000-28633750.000+4%-42838000.000+56%-45289300.000+65%-26701925.926-3%
Usd Free Cash Flow Per Share---0.186-0.194+4%-0.290+56%-0.307+65%-0.181-3%
Usd Free Cash Flow To Equity Per Share---0.185-0.194+4%-0.287+55%-0.152-18%0.014-1430%
Usd Market Cap1021246735.360+26%755604520.960621676571.200+22%1056296749.760-28%3184607413.632-76%2791866878.009-73%
Usd Price Per Share6.920+26%5.1204.213+22%7.158-28%21.579-76%18.918-73%
Usd Profit---32071000.000-48810250.000+52%-46092250.000+44%-45657200.000+42%-37318000.000+16%
Usd Revenue--46435000.00044320500.000+5%44922500.000+3%38200850.000+22%32612666.667+42%
Usd Total Gains Per Share---0.121-0.234+93%-0.214+77%-0.123+1%0.056-316%
 EOD+5 -3MRQTTM+27 -11YOY+21 -175Y+19 -1910Y+12 -26

3.3 Fundamental Score

Let's check the fundamental score of Adaptive Biotechnologies Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.961
Price to Book Ratio (EOD)Between0-14.568
Net Profit Margin (MRQ)Greater than0-0.691
Operating Margin (MRQ)Greater than0-0.628
Quick Ratio (MRQ)Greater than15.585
Current Ratio (MRQ)Greater than13.519
Debt to Asset Ratio (MRQ)Less than10.600
Debt to Equity Ratio (MRQ)Less than11.497
Return on Equity (MRQ)Greater than0.15-0.143
Return on Assets (MRQ)Greater than0.05-0.057
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Adaptive Biotechnologies Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.454
Ma 20Greater thanMa 506.488
Ma 50Greater thanMa 1006.048
Ma 100Greater thanMa 2005.384
OpenGreater thanClose7.190
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Fundamental data was last updated by Penke on 2025-01-16 11:47:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Adaptive Biotechnologies Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A Net Profit Margin of -69.1% means that $-0.69 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adaptive Biotechnologies Corp:

  • The MRQ is -69.1%. The company is making a huge loss. -2
  • The TTM is -110.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-69.1%TTM-110.3%+41.2%
TTM-110.3%YOY-109.7%-0.6%
TTM-110.3%5Y-123.7%+13.4%
5Y-123.7%10Y-115.0%-8.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-69.1%-104.6%+35.5%
TTM-110.3%-216.4%+106.1%
YOY-109.7%-208.6%+98.9%
5Y-123.7%-353.9%+230.2%
10Y-115.0%-488.0%+373.0%
4.3.1.2. Return on Assets

Shows how efficient Adaptive Biotechnologies Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • -5.7% Return on Assets means that Adaptive Biotechnologies Corp generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adaptive Biotechnologies Corp:

  • The MRQ is -5.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.7%TTM-8.0%+2.2%
TTM-8.0%YOY-6.0%-2.0%
TTM-8.0%5Y-5.6%-2.3%
5Y-5.6%10Y-4.6%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.7%-12.7%+7.0%
TTM-8.0%-13.0%+5.0%
YOY-6.0%-12.3%+6.3%
5Y-5.6%-13.7%+8.1%
10Y-4.6%-15.7%+11.1%
4.3.1.3. Return on Equity

Shows how efficient Adaptive Biotechnologies Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • -14.3% Return on Equity means Adaptive Biotechnologies Corp generated $-0.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adaptive Biotechnologies Corp:

  • The MRQ is -14.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.3%TTM-18.3%+4.0%
TTM-18.3%YOY-11.5%-6.9%
TTM-18.3%5Y-10.4%-7.9%
5Y-10.4%10Y-8.0%-2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.3%-16.8%+2.5%
TTM-18.3%-17.8%-0.5%
YOY-11.5%-16.4%+4.9%
5Y-10.4%-20.6%+10.2%
10Y-8.0%-21.2%+13.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adaptive Biotechnologies Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Adaptive Biotechnologies Corp is operating .

  • Measures how much profit Adaptive Biotechnologies Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • An Operating Margin of -62.8% means the company generated $-0.63  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adaptive Biotechnologies Corp:

  • The MRQ is -62.8%. The company is operating very inefficient. -2
  • The TTM is -103.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-62.8%TTM-103.8%+41.0%
TTM-103.8%YOY-107.2%+3.4%
TTM-103.8%5Y-120.1%+16.3%
5Y-120.1%10Y-113.3%-6.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-62.8%-193.6%+130.8%
TTM-103.8%-321.1%+217.3%
YOY-107.2%-227.9%+120.7%
5Y-120.1%-373.0%+252.9%
10Y-113.3%-506.1%+392.8%
4.3.2.2. Operating Ratio

Measures how efficient Adaptive Biotechnologies Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.70 means that the operating costs are $1.70 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 1.703. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.944. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.703TTM1.944-0.242
TTM1.944YOY2.138-0.193
TTM1.9445Y2.241-0.297
5Y2.24110Y2.173+0.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7032.171-0.468
TTM1.9443.250-1.306
YOY2.1383.231-1.093
5Y2.2414.838-2.597
10Y2.1736.440-4.267
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adaptive Biotechnologies Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.52 means the company has $3.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 3.519. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.169. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.519TTM4.169-0.651
TTM4.169YOY5.088-0.918
TTM4.1695Y5.371-1.202
5Y5.37110Y5.063+0.308
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5193.610-0.091
TTM4.1693.850+0.319
YOY5.0884.605+0.483
5Y5.3715.895-0.524
10Y5.0636.178-1.115
4.4.3.2. Quick Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A Quick Ratio of 5.58 means the company can pay off $5.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 5.585. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.648. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.585TTM6.648-1.063
TTM6.648YOY8.243-1.595
TTM6.6485Y8.433-1.785
5Y8.43310Y8.098+0.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5853.034+2.551
TTM6.6483.355+3.293
YOY8.2434.297+3.946
5Y8.4335.890+2.543
10Y8.0986.434+1.664
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adaptive Biotechnologies Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Adaptive Biotechnologies Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Adaptive Biotechnologies Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.60 means that Adaptive Biotechnologies Corp assets are financed with 60.0% credit (debt) and the remaining percentage (100% - 60.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 0.600. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.569. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.600TTM0.569+0.030
TTM0.569YOY0.475+0.094
TTM0.5695Y0.422+0.148
5Y0.42210Y0.466-0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6000.341+0.259
TTM0.5690.343+0.226
YOY0.4750.310+0.165
5Y0.4220.366+0.056
10Y0.4660.385+0.081
4.5.4.2. Debt to Equity Ratio

Measures if Adaptive Biotechnologies Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 149.7% means that company has $1.50 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adaptive Biotechnologies Corp:

  • The MRQ is 1.497. The company is able to pay all its debts with equity. +1
  • The TTM is 1.330. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.497TTM1.330+0.167
TTM1.330YOY0.907+0.423
TTM1.3305Y0.780+0.550
5Y0.78010Y0.641+0.139
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4970.393+1.104
TTM1.3300.429+0.901
YOY0.9070.382+0.525
5Y0.7800.439+0.341
10Y0.6410.489+0.152
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Adaptive Biotechnologies Corp generates.

  • Above 15 is considered overpriced but always compare Adaptive Biotechnologies Corp to the Biotechnology industry mean.
  • A PE ratio of -5.89 means the investor is paying $-5.89 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is -7.961. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.890. Based on the earnings, the company is expensive. -2
  • The TTM is -3.469. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.961MRQ-5.890-2.071
MRQ-5.890TTM-3.469-2.421
TTM-3.469YOY-5.462+1.993
TTM-3.4695Y-19.953+16.484
5Y-19.95310Y-21.839+1.886
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.961-2.247-5.714
MRQ-5.890-2.693-3.197
TTM-3.469-3.214-0.255
YOY-5.462-3.335-2.127
5Y-19.953-6.368-13.585
10Y-21.839-6.692-15.147
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is -9.315. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.892. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.821. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.315MRQ-6.892-2.423
MRQ-6.892TTM-5.821-1.071
TTM-5.821YOY-6.764+0.942
TTM-5.8215Y-17.643+11.822
5Y-17.64310Y-18.100+0.457
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.315-2.993-6.322
MRQ-6.892-3.671-3.221
TTM-5.821-4.037-1.784
YOY-6.764-4.482-2.282
5Y-17.643-8.190-9.453
10Y-18.100-9.383-8.717
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Adaptive Biotechnologies Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.38 means the investor is paying $3.38 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adaptive Biotechnologies Corp:

  • The EOD is 4.568. Based on the equity, the company is fair priced.
  • The MRQ is 3.380. Based on the equity, the company is fair priced.
  • The TTM is 2.416. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.568MRQ3.380+1.188
MRQ3.380TTM2.416+0.964
TTM2.416YOY2.557-0.141
TTM2.4165Y5.456-3.041
5Y5.45610Y3.402+2.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5681.933+2.635
MRQ3.3802.265+1.115
TTM2.4162.447-0.031
YOY2.5572.454+0.103
5Y5.4563.664+1.792
10Y3.4024.239-0.837
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adaptive Biotechnologies Corp.

4.8.1. Institutions holding Adaptive Biotechnologies Corp

Institutions are holding 93.869% of the shares of Adaptive Biotechnologies Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Viking Global Investors LP20.32380.55972999370800
2024-09-30Rubric Capital Management LP9.75751.2014144000004000002.8571
2024-09-30BlackRock Inc8.08570.0013119328412688392.3049
2024-09-30ARK Investment Management LLC7.86090.5432116011341891341.6573
2024-09-30Vanguard Group Inc7.20930.001106394404125294.0338
2024-09-30Millennium Management LLC6.36980.022894005731382321.4924
2024-09-30Nikko Asset Management Americas Inc5.24050.4477773388481410611.7649
2024-09-30Sumitomo Mitsui Trust Group Inc5.24050.0274773388483425312.0913
2024-09-30Aristotle Atlantic Partners, LLC2.03360.47783001201270130.9082
2024-09-30Massachusetts Financial Services Company1.95240.00442881364-1030663-26.346
2024-09-30Geode Capital Management, LLC1.80370.00112661878-20450-0.7624
2024-09-30State Street Corp1.72910.00052551785488851.9531
2024-09-30Blue Water Life Science Advisors, LLC1.45369.6593214514521451450
2024-09-30Goldman Sachs Group Inc1.18520.0014174914770113566.9014
2024-09-30Dimensional Fund Advisors, Inc.0.96290.00181420995518983.7907
2024-09-30Pictet Asset Manangement SA0.88210.00721301783-380222-22.6053
2024-09-30Pier Capital, LLC0.86450.9205127588522058620.9027
2024-09-30Soleus Capital Management, L.P.0.7540.44111112749-607251-35.3053
2024-09-30Morgan Stanley - Brokerage Accounts0.71020.00041048132152121.4727
2024-09-30abrdn PLC0.69760.0097102944700
Total 85.116914.3297125614975+4228381+3.4%

4.9.2. Funds holding Adaptive Biotechnologies Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30ARK Genomic Revolution7.80714.4371115216712437722.1615
2024-12-30ARK Genomic Revolution ETF6.6335.38369788966-138976-1.3998
2024-11-30Nikko AM ARK Pstv Chg Innovt P JPY Acc3.73881.38565517752-266537-4.6079
2024-11-30Vanguard Total Stock Mkt Idx Inv2.84470.0014419826700
2024-12-31iShares Russell 2000 ETF2.12040.02613129257-12025-0.3828
2024-06-07Nikko Gbl All Biological Genome Eq MF1.39623.60762060482-121818-5.5821
2024-11-30Vanguard Small Cap Index1.19920.00621769707103500.5883
2024-11-30Vanguard Institutional Extnd Mkt Idx Tr1.18970.00861755781104560.5991
2024-04-15Pictet Biopharmaceutical Mother1.18180.3919174410719250712.407
2024-11-30MFS New Discovery I1.13850.4143168015700
2024-10-31Fidelity Small Cap Index0.8020.0213118360759900.5087
2024-11-30Voya Small Cap Growth I0.73540.4781108526010563073648.3508
2024-12-31iShares Russell 2000 Value ETF0.73410.05271083317-30324-2.723
2024-11-30Vanguard Small Cap Growth Index Inv0.65990.014197390963000.6511
2024-12-31iShares Biotechnology ETF0.62560.0863923291-6657-0.7158
2024-11-30BlackRock Advantage Small Cap Core Instl0.5780.113385299400
2024-12-31State St Russell Sm/Mid Cp® Indx NL Cl C0.5130.0101757092-14200-1.8411
2024-12-31abrdn Healthcare Investors0.42750.3805630848-78789-11.1027
2024-11-30Fidelity Extended Market Index0.42210.0083622918-4106-0.6548
2024-11-30Vanguard Russell 2000 ETF0.36710.0232541811143562.7217
Total 35.114116.850351821194+866606+1.7%

5.3. Insider Transactions

Insiders are holding 1.926% of the shares of Adaptive Biotechnologies Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-18Kyle PiskelSELL2484.98
2024-03-05Chad M RobinsSELL486733.43
2024-03-05Julie RubinsteinSELL390703.47
2024-03-05Kyle PiskelSELL77273.43
2024-03-05Stacy L TaylorSELL133813.43
2024-03-05Tycho PetersonSELL154563.44
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets558,506
Total Liabilities334,932
Total Stockholder Equity223,773
 As reported
Total Liabilities 334,932
Total Stockholder Equity+ 223,773
Total Assets = 558,506

Assets

Total Assets558,506
Total Current Assets308,345
Long-term Assets250,161
Total Current Assets
Cash And Cash Equivalents 38,084
Short-term Investments 205,245
Net Receivables 40,814
Inventory 11,955
Other Current Assets 12,247
Total Current Assets  (as reported)308,345
Total Current Assets  (calculated)308,345
+/-0
Long-term Assets
Property Plant Equipment 97,844
Goodwill 118,972
Intangible Assets 3,853
Long-term Assets Other 5,626
Long-term Assets  (as reported)250,161
Long-term Assets  (calculated)226,295
+/- 23,866

Liabilities & Shareholders' Equity

Total Current Liabilities87,627
Long-term Liabilities247,305
Total Stockholder Equity223,773
Total Current Liabilities
Short-term Debt 10,021
Accounts payable 7,351
Other Current Liabilities 18,399
Total Current Liabilities  (as reported)87,627
Total Current Liabilities  (calculated)35,771
+/- 51,856
Long-term Liabilities
Long-term Liabilities  (as reported)247,305
Long-term Liabilities  (calculated)0
+/- 247,305
Total Stockholder Equity
Common Stock14
Retained Earnings -1,270,132
Other Stockholders Equity 1,493,891
Total Stockholder Equity (as reported)223,773
Total Stockholder Equity (calculated)223,773
+/-0
Other
Cash and Short Term Investments 243,329
Common Stock Shares Outstanding 147,516
Current Deferred Revenue51,856
Liabilities and Stockholders Equity 558,506
Net Debt 53,741
Net Working Capital 220,718
Short Long Term Debt Total 91,825



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
332,688
614,584
601,395
917,392
912,302
874,886
854,822
1,095,473
1,116,414
1,072,093
1,033,374
992,607
923,344
858,193
806,633
884,208
856,617
791,463
764,540
717,682
661,134
620,323
584,872
558,506
558,506584,872620,323661,134717,682764,540791,463856,617884,208806,633858,193923,344992,6071,033,3741,072,0931,116,4141,095,473854,822874,886912,302917,392601,395614,584332,688000
   > Total Current Assets 
0
0
0
180,718
459,148
442,301
601,356
612,690
584,646
599,521
877,358
726,914
764,960
643,729
467,027
402,748
419,120
438,575
564,380
562,146
501,333
476,809
435,237
410,188
374,034
351,552
308,345
308,345351,552374,034410,188435,237476,809501,333562,146564,380438,575419,120402,748467,027643,729764,960726,914877,358599,521584,646612,690601,356442,301459,148180,718000
       Cash And Cash Equivalents 
0
0
0
55,030
111,290
48,458
74,941
96,576
212,688
365,440
497,076
123,436
173,624
184,186
122,401
139,065
114,805
76,412
217,552
90,030
94,612
109,240
88,713
65,064
71,233
59,824
38,084
38,08459,82471,23365,06488,713109,24094,61290,030217,55276,412114,805139,065122,401184,186173,624123,436497,076365,440212,68896,57674,94148,458111,29055,030000
       Short-term Investments 
0
0
0
109,988
329,150
374,543
498,487
480,290
342,485
204,940
338,004
564,833
540,640
414,227
292,639
213,996
248,757
307,326
290,527
408,166
346,083
307,990
282,419
281,337
237,639
232,056
205,245
205,245232,056237,639281,337282,419307,990346,083408,166290,527307,326248,757213,996292,639414,227540,640564,833338,004204,940342,485480,290498,487374,543329,150109,988000
       Net Receivables 
0
0
0
4,807
4,066
7,252
9,257
12,676
9,382
7,914
11,858
10,047
19,754
14,174
17,122
17,409
22,518
23,712
26,549
40,057
30,972
31,545
31,211
37,969
42,021
35,610
40,814
40,81435,61042,02137,96931,21131,54530,97240,05726,54923,71222,51817,40917,12214,17419,75410,04711,8587,9149,38212,6769,2577,2524,0664,807000
       Other Current Assets 
0
0
0
3,055
6,787
4,044
10,004
14,079
9,573
10,691
19,684
14,535
13,520
12,530
16,634
13,015
12,038
12,347
12,407
9,440
9,792
9,074
13,404
21,740
9,850
20,496
12,247
12,24720,4969,85021,74013,4049,0749,7929,44012,40712,34712,03813,01516,63412,53013,52014,53519,68410,6919,57314,07910,0044,0446,7873,055000
   > Long-term Assets 
0
0
0
151,970
155,436
159,094
316,036
299,612
290,240
255,301
218,115
389,500
307,133
389,645
525,580
520,596
439,073
368,058
319,828
294,471
290,130
287,731
282,445
250,946
246,289
233,320
250,161
250,161233,320246,289250,946282,445287,731290,130294,471319,828368,058439,073520,596525,580389,645307,133389,500218,115255,301290,240299,612316,036159,094155,436151,970000
       Property Plant Equipment 
0
0
0
19,125
21,184
22,298
46,542
60,355
56,010
64,452
68,889
139,042
144,812
167,302
177,266
172,940
171,628
171,250
169,267
164,210
160,254
156,499
152,012
120,323
116,259
103,939
97,844
97,844103,939116,259120,323152,012156,499160,254164,210169,267171,250171,628172,940177,266167,302144,812139,04268,88964,45256,01060,35546,54222,29821,18419,125000
       Goodwill 
0
0
0
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972
118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972118,972000
       Long Term Investments 
0
0
0
0
0
0
135,306
105,435
100,618
57,383
16,466
118,525
30,688
91,131
217,379
217,145
137,110
66,928
19,698
0
0
0
0
0
0
0
0
0000000019,69866,928137,110217,145217,37991,13130,688118,52516,46657,383100,618105,435135,306000000
       Intangible Assets 
0
0
0
13,626
13,207
12,784
12,356
11,928
11,504
11,081
10,653
10,225
9,806
9,383
8,955
8,526
8,107
7,684
7,256
6,827
6,408
5,985
5,557
5,128
4,705
4,281
3,853
3,8534,2814,7055,1285,5575,9856,4086,8277,2567,6848,1078,5268,9559,3839,80610,22510,65311,08111,50411,92812,35612,78413,20713,626000
       Other Assets 
0
0
0
0
2,073
5,040
2,860
39,529
3,136
3,413
3,135
2,736
2,855
2,857
3,008
3,013
3,256
3,224
4,635
4,462
4,496
0
0
0
0
0
0
0000004,4964,4624,6353,2243,2563,0133,0082,8572,8552,7363,1353,4133,13639,5292,8605,0402,0730000
> Total Liabilities 
0
0
0
590,800
326,486
885,769
331,467
341,263
323,323
324,883
320,426
373,148
346,376
340,064
341,064
319,242
304,938
288,317
396,394
392,519
367,511
368,573
356,045
352,856
345,557
343,442
334,932
334,932343,442345,557352,856356,045368,573367,511392,519396,394288,317304,938319,242341,064340,064346,376373,148320,426324,883323,323341,263331,467885,769326,486590,800000
   > Total Current Liabilities 
0
0
0
22,800
63,251
74,862
73,377
78,313
77,950
93,422
100,832
105,197
106,768
116,648
122,382
113,807
115,066
111,468
104,018
109,788
90,101
95,335
93,298
88,015
82,952
88,126
87,627
87,62788,12682,95288,01593,29895,33590,101109,788104,018111,468115,066113,807122,382116,648106,768105,197100,83293,42277,95078,31373,37774,86263,25122,800000
       Short-term Debt 
0
0
0
0
0
0
0
0
1,502
3,229
3,969
3,529
4,308
4,833
5,108
5,055
8,545
8,615
8,528
9,230
9,287
9,345
9,482
18,768
9,594
19,612
10,021
10,02119,6129,59418,7689,4829,3459,2879,2308,5288,6158,5455,0555,1084,8334,3083,5293,9693,2291,50200000000
       Accounts payable 
0
0
0
1,793
3,266
2,944
2,421
4,453
3,895
3,686
5,412
3,237
5,197
6,093
8,252
3,307
5,959
2,720
4,163
8,084
6,333
9,163
4,483
7,719
12,170
9,867
7,351
7,3519,86712,1707,7194,4839,1636,3338,0844,1632,7205,9593,3078,2526,0935,1973,2375,4123,6863,8954,4532,4212,9443,2661,793000
       Other Current Liabilities 
0
0
0
8,312
7,961
10,724
9,687
12,866
7,981
10,808
13,259
25,112
18,915
22,169
29,068
24,985
17,058
19,219
23,435
28,359
14,161
18,910
23,993
12,839
14,318
6,422
18,399
18,3996,42214,31812,83923,99318,91014,16128,35923,43519,21917,05824,98529,06822,16918,91525,11213,25910,8087,98112,8669,68710,7247,9618,312000
   > Long-term Liabilities 
0
0
0
568,000
263,235
810,907
258,090
262,950
245,373
231,461
219,594
267,951
239,608
223,416
218,682
205,435
189,872
176,849
292,376
282,731
277,410
273,238
262,747
264,841
262,605
255,316
247,305
247,305255,316262,605264,841262,747273,238277,410282,731292,376176,849189,872205,435218,682223,416239,608267,951219,594231,461245,373262,950258,090810,907263,235568,000000
       Long term Debt Total 
0
0
0
0
353
2,602
23,449
36,607
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000036,60723,4492,6023530000
       Other Liabilities 
0
0
0
0
263,235
246,374
234,641
226,343
208,828
188,958
177,228
163,618
144,356
119,642
110,638
98,750
84,894
74,122
191,855
183,959
180,916
0
0
0
0
0
0
000000180,916183,959191,85574,12284,89498,750110,638119,642144,356163,618177,228188,958208,828226,343234,641246,374263,2350000
       Deferred Long Term Liability 
0
0
0
0
0
4,800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000004,80000000
> Total Stockholder Equity
-224,616
0
0
-258,112
288,098
-284,374
585,925
571,039
551,563
529,939
775,047
743,266
725,588
693,181
651,509
603,992
553,205
518,304
487,840
464,165
424,020
396,036
361,732
308,399
274,913
241,603
223,773
223,773241,603274,913308,399361,732396,036424,020464,165487,840518,304553,205603,992651,509693,181725,588743,266775,047529,939551,563571,039585,925-284,374288,098-258,11200-224,616
   Common Stock
0
0
0
1
11
1
12
12
12
12
13
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
1414141414141414141414141414141413121212121111000
   Retained Earnings Total Equity000000-976,781-919,082-878,954-833,673-781,627-718,891-657,458-601,555-552,254-511,61200000000000
   Accumulated Other Comprehensive Income 
0
0
0
-107
92
382
572
671
3,313
2,153
1,427
893
631
216
7
-1,137
-4,783
-5,800
-5,971
-4,116
-1,905
-893
-250
215
-106
-182
497
497-182-106215-250-893-1,905-4,116-5,971-5,800-4,783-1,13772166318931,4272,1533,31367157238292-107000
   Capital Surplus 
0
0
0
0
40,981
46,160
930,208
935,834
945,026
0
0
1,253,971
1,277,197
1,294,506
1,308,946
1,324,006
1,339,601
1,357,763
1,372,751
1,387,349
1,402,692
0
0
0
0
0
0
0000001,402,6921,387,3491,372,7511,357,7631,339,6011,324,0061,308,9461,294,5061,277,1971,253,97100945,026935,834930,20846,16040,9810000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
0
0
0
37,902
602,543
43,558
12,816
935,834
945,026
958,097
1,240,649
1,253,971
1,277,197
1,294,506
1,308,946
1,324,006
1,339,601
1,357,763
1,372,751
1,387,349
1,402,692
1,421,506
1,436,859
1,452,502
1,466,844
1,479,832
1,493,891
1,493,8911,479,8321,466,8441,452,5021,436,8591,421,5061,402,6921,387,3491,372,7511,357,7631,339,6011,324,0061,308,9461,294,5061,277,1971,253,9711,240,649958,097945,026935,83412,81643,558602,54337,902000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue170,276
Cost of Revenue-75,553
Gross Profit94,72394,723
 
Operating Income (+$)
Gross Profit94,723
Operating Expense-321,758
Operating Income-227,035-227,035
 
Operating Expense (+$)
Research Development122,117
Selling General Administrative83,934
Selling And Marketing Expenses88,579
Operating Expense321,758294,630
 
Net Interest Income (+$)
Interest Income13,520
Interest Expense-13,800
Other Finance Cost-573
Net Interest Income-853
 
Pretax Income (+$)
Operating Income-227,035
Net Interest Income-853
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-225,304-228,766
EBIT - interestExpense = -225,304
-225,304
-211,450
Interest Expense13,800
Earnings Before Interest and Taxes (EBIT)-211,504-211,504
Earnings Before Interest and Taxes (EBITDA)-189,273
 
After tax Income (+$)
Income Before Tax-225,304
Tax Provision-0
Net Income From Continuing Ops-196,006-225,304
Net Income-225,250
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses397,311
Total Other Income/Expenses Net1,731853
 

Technical Analysis of Adaptive Biotechnologies Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adaptive Biotechnologies Corp. The general trend of Adaptive Biotechnologies Corp is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adaptive Biotechnologies Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adaptive Biotechnologies Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.46 < 8.51 < 8.95.

The bearish price targets are: 5.805 > 4.27 > 3.981.

Tweet this
Adaptive Biotechnologies Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adaptive Biotechnologies Corp. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adaptive Biotechnologies Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adaptive Biotechnologies Corp. The current macd is 0.21030775.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adaptive Biotechnologies Corp price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Adaptive Biotechnologies Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Adaptive Biotechnologies Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Adaptive Biotechnologies Corp Daily Moving Average Convergence/Divergence (MACD) ChartAdaptive Biotechnologies Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adaptive Biotechnologies Corp. The current adx is 24.30.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Adaptive Biotechnologies Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Adaptive Biotechnologies Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adaptive Biotechnologies Corp. The current sar is 7.401194.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Adaptive Biotechnologies Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adaptive Biotechnologies Corp. The current rsi is 56.45. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Adaptive Biotechnologies Corp Daily Relative Strength Index (RSI) ChartAdaptive Biotechnologies Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adaptive Biotechnologies Corp. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Adaptive Biotechnologies Corp price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Adaptive Biotechnologies Corp Daily Stochastic Oscillator ChartAdaptive Biotechnologies Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adaptive Biotechnologies Corp. The current cci is 87.73.

Adaptive Biotechnologies Corp Daily Commodity Channel Index (CCI) ChartAdaptive Biotechnologies Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adaptive Biotechnologies Corp. The current cmo is 13.42.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Adaptive Biotechnologies Corp Daily Chande Momentum Oscillator (CMO) ChartAdaptive Biotechnologies Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adaptive Biotechnologies Corp. The current willr is -34.83870968.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Adaptive Biotechnologies Corp is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Adaptive Biotechnologies Corp Daily Williams %R ChartAdaptive Biotechnologies Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adaptive Biotechnologies Corp. The current atr is 0.56597013.

Adaptive Biotechnologies Corp Daily Average True Range (ATR) ChartAdaptive Biotechnologies Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adaptive Biotechnologies Corp. The current obv is -13,883,203.

Adaptive Biotechnologies Corp Daily On-Balance Volume (OBV) ChartAdaptive Biotechnologies Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adaptive Biotechnologies Corp. The current mfi is 43.78.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Adaptive Biotechnologies Corp Daily Money Flow Index (MFI) ChartAdaptive Biotechnologies Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adaptive Biotechnologies Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Adaptive Biotechnologies Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adaptive Biotechnologies Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.454
Ma 20Greater thanMa 506.488
Ma 50Greater thanMa 1006.048
Ma 100Greater thanMa 2005.384
OpenGreater thanClose7.190
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Adaptive Biotechnologies Corp with someone you think should read this too:
  • Are you bullish or bearish on Adaptive Biotechnologies Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adaptive Biotechnologies Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adaptive Biotechnologies Corp

I send you an email if I find something interesting about Adaptive Biotechnologies Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Adaptive Biotechnologies Corp.

Receive notifications about Adaptive Biotechnologies Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.